Sitagliptin

CAS 486460-32-6 51 API suppliersSmall Molecule

Overview

Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an oral antihyperglycemic agent for the treatment of type 2 diabetes. It works by increasing incretin levels, which inhibit glucagon release, thereby increasing insulin secretion.

API suppliers (51)

Suppliers of Sitagliptin evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India25China11Spain3Netherlands1Pakistan1Israel1Canada1France1

Country recorded for 44 of 51 suppliers.

22 of 51 hold a GMP certificate on record in the EU or UK registers

Showing 25 of 51 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (16 approved US products), the latest listed US patent on Sitagliptin expires 23 Oct 2040 and exclusivity 24 Nov 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

DiabetesEndocrinologyMetabolic Disorders
Verified Supplier Partner

Do you supply Sitagliptin? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.